Overview of Teplizumab for Delaying Onset and Progression of Type 1 Diabetes

Opinion
Video

Panelists discuss how teplizumab, the first FDA-approved disease-modifying therapy for Type 1 diabetes, can delay disease onset by targeting CD3+ T cells and preserving beta cell function in high-risk individuals.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
      Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
      Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
      Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
      US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
      US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
      Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
      Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
      Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
      Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
      VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
      VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
      DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
      DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
      A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
      A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
      Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
      Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
      Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
      Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
      Related Content
      Novel Non-Invasive Glucose Monitor Uses Light-Based Technology / image credit RSP Systems

      Novel Non-Invasive Glucose Monitor Uses Light-Based Technology

      Todd Shryock
      April 11th 2025
      Article

      Accuracy of data recorded with the GlucoBeam was found to be comparable to standard finger-stick blood glucose tests.

      Obesity & Type 2 Diabetes: An Expert Discussion

      Obesity & Type 2 Diabetes: An Expert Discussion

      Sydney Jennings
      June 30th 2023
      Podcast

      In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

      Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin Plus CGM

      Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin with CGM

      Grace Halsey
      March 27th 2025
      Article

      Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.

      Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

      Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

      Sydney Jennings
      July 22nd 2022
      Podcast

      "Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

      Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

      Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

      Grace Halsey
      March 14th 2025
      Article

      A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

      Bionic Pancreas for Type 1 Diabetes Found Feasible to Implement in Primary Care

      Bionic Pancreas for Type 1 Diabetes Found Feasible to Implement in Primary Care

      Sydney Jennings
      March 14th 2025
      Article

      The iLet bionic pancreas system conferred an average glucose of less than 183 mg/dL in 97% of adults with T1D in a small study.

      © 2025 MJH Life Sciences

      All rights reserved.